SCHEMBL4516445

SCHEMBL4516445

CCOC(=O)c1cc(F)c(N2CCC(NC(=O)OC(C)(C)C)C2)c(F)c1NC1CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.38
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
PIM1 P11309 1/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
OPRK1 P41145 2/20 0.37
BTK Q06187 3/20 0.37
KDM4D Q6B0I6 3/20 0.36
PDE10A Q9Y233 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
SYK P43405 1/20 0.36
JAK3 P52333 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4516438 1.00 CTSK (0.38) CTSKDRD2DRD3PIM1PIM3
SCHEMBL4514369 0.93 BTK (0.38) CTSKDRD2DRD3PIM1PIM3
SCHEMBL4515754 0.91 DRD2 (0.40) CTSKDRD2DRD3BTKKDM4D
SCHEMBL4515747 0.91 DRD2 (0.40) CTSKDRD2DRD3BTKKDM4D
SCHEMBL4507973 0.91 DRD2 (0.40) CTSKDRD2DRD3BTKKDM4D
SCHEMBL4519007 0.91 SUV39H2 (0.40) DRD2DRD3KDM4D
SCHEMBL13713214 0.91 DRD2 (0.43) CTSKDRD2DRD3PIM1PIM3
SCHEMBL4502331 0.91 DRD2 (0.38) CTSKDRD2DRD3PIM1PIM3
SCHEMBL4519444 0.90 CTSK (0.41) CTSKDRD2DRD3PIM1PIM3
SCHEMBL4519448 0.90 CTSK (0.41) CTSKDRD2DRD3PIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582627-B2 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase WARNER-LAMBERT COMPANY (US) 2009-09-01 US disclosed
EP-1255739-B1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2008-06-11 EP disclosed
US-20060287308-A1 3-Aminoquinazolin-2,4-dione antibacterial agents ZOETIS WLC LLC 2006-12-21 US disclosed
US-7094780-B1 3-aminoquinazolin-2,4-dione antibacterial agents WARNER LAMBERT COMPANY LLC (US) 2006-08-22 US disclosed
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ZOETIS WLC LLC 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ABL1, NQO2, CBR3 CTSK 646/4885DRD2 81/4885DRD3 40/4885
US-20060287308-A1 3-Aminoquinazolin-2,4-dione antibacterial agents ABL1, NQO2, AAAS CTSK 632/4885DRD2 82/4885DRD3 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.